Home › Funds › Direxion Shares ETF Trust › Direxion Daily S&P Biotech Bull 3X ETF
Fund family: Direxion Shares ETF Trust · Filed by Direxion Shares ETF Trust (CIK 1424958) · SEC series S000049373
Ticker: LABU (C000156149)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 967 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 2 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Direxion Shares ETF Trust’s manager page (28,641 ballot items across 25 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Direxion Shares ETF Trust | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 77.9% | 944 | 94.4% | 26,237 |
| Backed environmental and social shareholder proposals at US companies | n/a | 2 | 11.0% | 620 |
Each ballot item this fund voted is set against the votes of the other Direxion Shares ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most Direxion Shares ETF Trust funds on all 78 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 96.1% of this fund’s 973 such votes could be given a sector; the other 38 (3.9%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 935 | 6 | 0.6% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 583 | 0 |
| Say-on-Pay | 150 | 0 |
| Audit-related | 138 | 0 |
| Compensation | 74 | 0 |
| Corporate Governance | 26 | 4 |
| Capital Structure | 18 | 0 |
| Extraordinary Transactions | 5 | 0 |
| Environment or Climate | 1 | 1 |
| Other Social Issues | 1 | 1 |
| Shareholder Rights and Defenses | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Moderna, Inc. | November 12, 2025 | $56M | 2 | 0 |
| Moderna, Inc. | May 6, 2026 | $27M | 5 | 0 |
| Twist Bioscience Corporation | February 5, 2026 | $9M | 5 | 0 |
| Travere Therapeutics, Inc. | May 19, 2026 | $4M | 14 | 0 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $4M | 14 | 1 |
| Rhythm Pharmaceuticals, Inc. | June 24, 2026 | $3M | 4 | 0 |
| Madrigal Pharmaceuticals, Inc. | June 17, 2026 | $3M | 7 | 0 |
| Revolution Medicines, Inc. | June 18, 2026 | $3M | 4 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
997 ballot items at 144 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Direxion Daily S&P Biotech Bull 3X ETF (LABU) voted at 144 shareholder meetings of 142 companies, on 997 ballot items in all. Where management made a recommendation, the fund followed it on 99.4% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than Direxion Shares ETF Trust's funds as a whole (77.9% against 94.4%). It voted the same way as most Direxion Shares ETF Trust funds on every item where a comparison was possible. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Direxion Shares ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.